Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A

Alzheimers Dement. 2022 Feb;18(2):222-239. doi: 10.1002/alz.12398. Epub 2021 Jun 20.

Abstract

The Ca2+ hypothesis for Alzheimer's disease (AD) conceives Ca2+ dyshomeostasis as a common mechanism of AD; the cause of Ca2+ dysregulation, however, is obscure. Meanwhile, hyperactivities of N-Methyl-D-aspartate receptors (NMDARs), the primary mediator of Ca2+ influx, are reported in AD. GluN3A (NR3A) is an NMDAR inhibitory subunit. We hypothesize that GluN3A is critical for sustained Ca2+ homeostasis and its deficiency is pathogenic for AD. Cellular, molecular, and functional changes were examined in adult/aging GluN3A knockout (KO) mice. The GluN3A KO mouse brain displayed age-dependent moderate but persistent neuronal hyperactivity, elevated intracellular Ca2+ , neuroinflammation, impaired synaptic integrity/plasticity, and neuronal loss. GluN3A KO mice developed olfactory dysfunction followed by psychological/cognitive deficits prior to amyloid-β/tau pathology. Memantine at preclinical stage prevented/attenuated AD syndromes. AD patients' brains show reduced GluN3A expression. We propose that chronic "degenerative excitotoxicity" leads to sporadic AD, while GluN3A represents a primary pathogenic factor, an early biomarker, and an amyloid-independent therapeutic target.

Keywords: Alzheimer's disease; N-methyl-d-aspartate receptor; NR3A; degenerative excitotoxicity; dementia; prevention; subhealth status.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Alzheimer Disease* / metabolism
  • Animals
  • Humans
  • Memantine / pharmacology
  • Memantine / therapeutic use
  • Mice
  • Mice, Knockout
  • Neurons / metabolism
  • Receptors, N-Methyl-D-Aspartate* / genetics

Substances

  • GRIN3A protein, human
  • GluN3A protein, mouse
  • Receptors, N-Methyl-D-Aspartate
  • Memantine